Tech Company Financing Transactions
Metacrine Funding Round
On 8/5/2015, Metacrine raised $36 million in Series A financing from Arch Venture Partners, EcoR1 Capital Management and Polaris Partners.
Transaction Overview
Company Name
Announced On
8/5/2015
Transaction Type
Venture Equity
Amount
$36,000,000
Round
Series A
Investors
Proceeds Purpose
elop two classes of novel therapeutics, to target diabetes, non-alcoholic steatohepatitis (NASH) and other metabolic diseases and liver disorders.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
3985 Sorrento Valley Blvd. C
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
Metacrine (Nasdaq: MTCR) is a biotech company founded in 2015 on technology licensed from the laboratory of Dr. Ronald Evans, a world leader in nuclear hormone receptors and Howard Hughes Medical Institute Investigator at the Salk Institute.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Preston Klassen
Chief Financial Officer
Trisha Millican
Vice President
Nicholas Smith
VP - Operations
Eric Bischoff
Browse more venture capital transactions:
Prev: 8/5/2015: Mevion Medical Systems venture capital transaction
Next: 8/6/2015: IncludeFitness venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs